Detection of Undiagnosed Diabetes and Other Hyperglycemia States: the Atherosclerosis Risk in Communities Study
Overview
Authors
Affiliations
Objective: To evaluate screening strategies based on fasting plasma glucose (FPG), clinical information, and the oral glucose tolerance test (OGTT) for detection of diabetes or other hyperglycemic states-impaired fasting glucose (IFG) and impaired glucose tolerance-meriting clinical intervention.
Research Design And Methods: We studied 8,286 African-American and white men and women without known diabetes, aged 53-75 years, who received an OGTT during the fourth exam of the Atherosclerosis Risk in Communities Study. Using a split sample technique, we estimated the diagnostic properties of various clinical detection rules derived from logistic regression modeling. Screening strategies utilizing FPG, these detection rules, and/or the OGTT were then compared in terms of both the fraction of hyperglycemia cases detected and the sample fraction receiving different screening tests and identified as screen positive.
Results: Screening based on the IFG cut point (> or =6.1 mmol/l), followed by a clinical detection rule for those below this value, detected 86.3% of diabetic case subjects and 66.0% of all hyperglycemia cases, identifying 42% of the sample as screen positive. Applying an OGTT for those positive by the rule provides diagnostic labeling and reduces the fraction that is screen positive to 29%. Another strategy, to apply an OGTT to those with an FPG cut point between 5.6 and 6.1 mmol/l, also identifies 29% of the sample as screen positive, although it detects slightly fewer hyperglycemia cases.
Conclusions: Screening strategies based on FPG, complemented by clinical detection rules and/or an OGTT, are effective and practical in the detection of hyperglycemic states meriting clinical intervention.
Kanellakis S, Mavrogianni C, Karatzi K, Lindstrom J, Cardon G, Iotova V Nutrients. 2020; 12(4).
PMID: 32235566 PMC: 7230581. DOI: 10.3390/nu12040960.
Wells B, Lenoir K, Diaz-Garelli J, Futrell W, Lockerman E, Pantalone K JMIR Med Inform. 2018; 6(4):e10780.
PMID: 30348631 PMC: 6231807. DOI: 10.2196/10780.
Shahim B, Gyberg V, De Bacquer D, Kotseva K, De Backer G, Schnell O Cardiovasc Diabetol. 2018; 17(1):21.
PMID: 29368616 PMC: 5781265. DOI: 10.1186/s12933-018-0665-4.
Kulkarni M, Foraker R, McNeill A, Girman C, Golden S, Rosamond W Diabetes Obes Metab. 2017; 19(9):1260-1266.
PMID: 28321981 PMC: 5568921. DOI: 10.1111/dom.12949.
Alghadir A, Alghwiri A, Awad H, Anwer S Medicine (Baltimore). 2016; 95(12):e3181.
PMID: 27015209 PMC: 4998404. DOI: 10.1097/MD.0000000000003181.